Empagliflozin - Boehringer Ingelheim/Eli Lilly

Drug Profile

Empagliflozin - Boehringer Ingelheim/Eli Lilly

Alternative Names: BI-10773; Jardiance

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly; Medical University of Vienna; RWTH Aachen University; University of Oxford; Yale University
  • Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Cyclic ethers; Glucosides; Heart failure therapies; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Type 2 diabetes mellitus
  • Phase III Chronic heart failure; Heart failure; Renal failure; Type 1 diabetes mellitus
  • Phase II Acute heart failure

Most Recent Events

  • 02 Jul 2018 Committee for Medicinal Products for Human Use (CHMP) issues positive opinion to expand Jardiance® label to include positive effects on cardiovascular and renal outcomes in European union
  • 25 Jun 2018 Safety data from the phase III EASE 2 and EASE 3 trial in Type 1 diabetes mellitus released by Boehringer Ingelheim and Eli Lilly
  • 11 Jun 2018 Phase-II clinical trials in Acute heart failure in Germany (PO) (NCT03554200)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top